A 1-Bag/4-Step Rapid Desensitization Protocol to Reintroduce Agalsidase a in a Patient With Fabry Disease.

Autor: Jimenez-Rodriguez TW; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII). Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain., Soriano Gomis V; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII). Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.; Department of Clinical Medicine, Miguel Hernández University, San Juan, Alicante, Spain., Burgos San-José A; Pharmacy Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Montoyo Antón RA; Oncology Day Hospital Nursing Service, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., González Delgado MP; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII). Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.; Department of Clinical Medicine, Miguel Hernández University, San Juan, Alicante, Spain., Gallego Velez CP; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Ortolano S; Rare Diseases and Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain., Fernández J; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII). Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.; Department of Clinical Medicine, Miguel Hernández University, San Juan, Alicante, Spain., Sánchez Martínez R; Internal Medicine Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

Publikováno v: Journal of investigational allergology & clinical immunology [J Investig Allergol Clin Immunol] 2024 Dec 02, pp. 0. Date of Electronic Publication: 2024 Dec 02.

Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients

Autor: Eva González-Haba-Peña, Margarita Garrido-Siles, María Jose Martínez-Bautista, Amparo Burgos-San José, Azucena Aldaz-Pastor, Irene Mangues-Bafalluy

Publikováno v: Farmacia Hospitalaria, Vol 44, Iss 5, Pp 192-197 (2020)

Objective: To analyze the excipients and impurities contained in the various docetaxel products available on the market and find out whether they may be responsible for any of the different adverse events associated with the use of docetaxel in patie

Externí odkaz: https://doaj.org/article/c5f185ed05804a53aff7ad73385191b5

Efectividad y seguridad de atezolizumab, nivolumab y pembrolizumab en cáncer de pulmón no microcítico metastásico. (Spanish)

Autor: Burgos-San José, Amparo, Colomer-Aguilar, Claudia, Martínez-Caballero, Daniel, Massutí-Sureda, Bartomeu

Publikováno v: Farmacia Hospitalaria (1130-6343); may/jun2021, Vol. 45 Issue 3, p121-125, 5p

Assessing the risk of using hazardous drugs in Hospital-at-Home Units: a big data study protocol

Autor: Mari A, Bernabeu-Martínez, Pedro, García-Salom, Amparo, Burgos-San José, Luis M, Álvarez-Sabucedo, Carmina, Wanden-Berghe, Javier, Sanz-Valero

Publikováno v: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 45(5)

This article describes a study protocol for the implementation of quality and traceability control in the hazardous medication circuit through an analysis of risks and the development and introduction of a Big Data-based software application aimed at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::77c4d6345bcbbcdaf7028fd6ee419aab
https://pubmed.ncbi.nlm.nih.gov/34806590

Assessing the risk of using hazardous drugs in Hospital-at-Home Units: a big data study protocol

Autor: Bernabeu-Martínez, Mari A, García-Salom, Pedro, Burgos-San José, Amparo, Álvarez-Sabucedo, Luis M, Wanden-Berghe, Carmina, Sanz-Valero, Javier

Publikováno v: Repisalud
Instituto de Salud Carlos III (ISCIII)

Incluye versión en español e inglés [ES] Objetivo: Describir el protocolo del estudio para la instauración del control del proceso de los medicamentos peligrosos que asegure la calidad y su trazabilidad, mediante el análisis de riesgos, desarrol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a262af37bce7135a70314a67f0d9f703
https://hdl.handle.net/20.500.12105/14122